Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients
暂无分享,去创建一个
Federica Fioroni | Annibale Versari | Emmanuel Itti | Michel Meignan | Stefano Luminari | Francesco Merli | P. Gobbi | F. Merli | A. Versari | M. Meignan | E. Itti | H. Masset | F. Fioroni | R. Casasnovas | Chiara Coriani | S. Luminari | Myriam Sasanelli | C. Coriani | Myriam Sasanelli | René Olivier Casasnovas | Helene Masset | Paolo G. Gobbi
[1] M. Dreyling,et al. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Ronald Boellaard,et al. Repeatability of Metabolically Active Volume Measurements with 18F-FDG and 18F-FLT PET in Non–Small Cell Lung Cancer , 2010, The Journal of Nuclear Medicine.
[3] H. Tilly,et al. Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL) , 2012 .
[4] S M Larson,et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.
[5] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[6] B. Coiffier,et al. Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma , 2012 .
[7] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[8] P. Moreau,et al. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma , 2008, Haematologica.
[9] U. Jaeger,et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.
[10] M. Dimopoulos,et al. Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents , 2013, Hematological oncology.
[11] Ho-Jin Shin,et al. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.
[12] G. Mahon. A Proposal for Strength-of-Agreement Criteria for Lin’s Concordance Correlation Coefficient , 2005 .
[13] L. Lin,et al. A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.
[14] Peter Smeets,et al. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[15] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[16] Nico Karssemeijer,et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET , 2007, Nuclear medicine communications.
[17] Robert B. McBride,et al. A proposal for strength-of-agreement criteria for Lins Concordance Correlation Coefficient , 2005 .
[18] Seong-Jang Kim,et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma , 2013, Cancer science.
[19] P. Gobbi,et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy , 2012, Hematological oncology.
[20] P. Moreau,et al. Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome. , 2007 .
[21] B. Coiffier,et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.
[22] Seong-Jang Kim,et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.
[23] Aswin L Hoffmann,et al. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.
[24] Paul Kinahan,et al. Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. , 2006, Medical physics.
[25] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Buvat,et al. Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET , 2010, Journal of Nuclear Medicine.
[27] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Barnhart,et al. An Overview on Assessing Agreement with Continuous Measurements , 2007, Journal of biopharmaceutical statistics.
[29] A. Alavi,et al. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET , 2008, Nuclear medicine communications.
[30] Andreas Bockisch,et al. Segmentation of PET volumes by iterative image thresholding. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] M. Federico,et al. Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy , 2011, Leukemia & lymphoma.
[32] C. Rübe,et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] A. López-Guillermo,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.
[34] S. Barrington,et al. does Quantitative Pet-ct Predict Prognosis In Diffuse Large Bcell Lymphoma (dlbcl)? : 014 , 2013 .
[35] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[36] M. Dreyling,et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.